Inogen reports huge increase in net income
Inogen, a maker of portable oxygen concentrators based in Goleta, announced a 77 percent increase in net income Feb. 28 on fourth quarter revenues of $50.9 million. Sales revenues grew 47.2 percent over the same quarter in 2015, to $42.6 million. Net income for the quarter was $5.3 million, bringing the company up to $20.5 Read More →
AppFolio revenues grow, losses shrink
AppFolio announced an increase in fourth quarter and full year revenues Feb. 27, decreasing its net losses per share by around a third compared to 2015. The Goleta-based company’s revenues for the quarter ended Dec. 31 grew 37 percent to $28 million, up from $20.4 million during the same period the prior year. Full year Read More →
Angel investors weigh person making pitch
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Santa Barbara’s Sandbox incubator debuts with virtual reality forum
The region’s newest business workspace made its public debut Feb. 23 with the opening of Sandbox, a medium-sized business incubator at 414 Olive St. in Santa Barbara’s emerging Haley Street corridor. About 85 people attended a forum on “The Business of Virtual Reality” with VR experts and author Shel Israel. Sandbox is the brainchild of Read More →
Resonant agrees to sell $7.5 million in stock to Longboard
Goleta-based radio frequency front-end designer Resonant agreed to allow its stockholder Longboard Capital Advisors to purchase $7.5 million worth of stock and stock warrants. Expected to close Feb. 22, each unit in the offering will be sold for $4.61, the average closing price for Resonant common stock between Feb. 3 and Feb. 16. In addition, Read More →
The Trade Desk stock up 8 percent as firm sells 5 million shares
Shares of Ventura-based The Trade Desk jumped 8 percent to $35.00 as the company announced the launch of a 5 million share offering by current investors. At the company’s closing price on Feb. 21, the offering would have a gross value of around $165 million before a possible 10 percent overallotment, as disclosed in the Read More →
Genentech sues Amgen over biosimilar drug info
Roch AG subsidiary Genentech filed a lawsuit against Amgen claiming the Thousand Oaks-based company obstructed its investigation of whether the biosimilar Amgen is developing for Genentech’s cancer treatment Avastin violates the company’s patents, according to reports Feb. 20. Sales for Avastin, a treatment for lung, colon, ovarian and other types of cancer, reached $6.8 billion Read More →
